Akeso says ivonescimab met key secondary endpoint in Harmoni-2
Akeso Inc (HKEX:9926) said its ivonescimab met a key secondary endpoint in the Harmoni-2 study.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.